~~<i id='C20A07067A'><strike id='C20A07067A'><tt id='C20A07067A'><pre id='C20A07067A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

comprehensive

author：explore 2025-09-28 22:28:27 - browse：6287

WASHINGTON — Back in 1980, when the Food and Drug Administration approved the use of lead acetate in hair dyes, little was known about the way skin absorbs toxic chemicals.

The skin — and the scalp in particular — were considered tough barriers to break, and many public health officials believed that even if small amounts of lead got through, or were inhaled, it couldn’t really hurt anyone.

But in science, 37 years is an eon. So a coalition of environmental groups, academics, and consumer advocates is pushing FDA to take lead acetate off the market. It is now permitted as a color additive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： How generative AI ratchets up security threats for health systems

entertainment

Wikipedia

leisure time

entertainment

focus

AdobeTherearetimeswhenanewmedicaltechnologyisthrustintothepublicspotlightbecauseitseemslikeitmightso

WSS

6 solutions to address cancer drug shortages and others

New oral drug delivery patch is modeled after octopus tentacles

FTC sues over Novant Health acquisition of two N.C. hospitals

Philips to halt sales of sleep apnea machines in U.S.

Zyn nicotine pouches become unlikely player in latest culture war

Investment in vaccine development is lagging, report finds

entertainment

comprehensive

entertainment

Anesthesiologist group: stop taking Ozempic before surgery

What we owe ALS patients — and why one company fell short

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The stability of $0 premiums in Medicare Advantage

The cancer drug shortage isn’t new — and neither are the solutions

Congress extends some pandemic preparedness programs

Alkermes shareholders re

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Dobbs anniversary: the lost opportunity of abortion as health care

Humana’s losses in Medicare Advantage tank its stock

Wikipedia

The United States is paying nearly triple for new Covid vaccines

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Zyn nicotine pouches become unlikely player in latest culture war

How generative AI ratchets up security threats for health systems

Humana’s losses in Medicare Advantage tank its stock

What will Novo Nordisk's VC do with its influx of cash?

leisure time

entertainment

focus

focus